Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Nico Popp on August 14th, 2025 | 07:10 CEST

High flyers are emerging here: NetraMark, Bechtle, Adesso

  • Biotechnology
  • AI
  • IT

Sometimes you need an outside opinion. Consulting firms have been cashing in on this for decades. Especially when it comes to new technologies, fresh external input makes sense. McKinsey consultants estimate that the rapid deployment of modern technology alone can lead to productivity gains of 3% - year after year. No wonder, then, that external service providers are in demand in an increasing number of industries and are creating added value. We explain the opportunities these companies can offer investors.

Read

Commented by André Will-Laudien on August 13th, 2025 | 07:15 CEST

Attention, Takeovers: Things are heating up! Bayer, Eli Lilly, Vidac Pharma, and Formycon in focus

  • Biotechnology
  • Biotech
  • Pharma

Volatility is king! Great for speculators, often difficult for long-term investors. Biotech stocks are extremely sensitive to study and approval news, especially in cancer research. Vidac Pharma is developing drugs that are designed to target tumor cells and cause them to die – risky, but with great potential. Despite its restructuring, Bayer is strengthening its oncology pipeline, especially in niche indications. Eli Lilly is benefiting from the boom in modern immunotherapies and, thanks to its strong financial position, can support long development phases. Formycon is considering entering the oncology market to broaden its base. The sector offers opportunities and surprising takeovers, but requires a high tolerance for risk.

Read

Commented by Armin Schulz on August 13th, 2025 | 07:05 CEST

200% opportunity NOW: How Novo Nordisk, Dryden Gold, and Puma could boost your portfolio

  • Mining
  • Gold
  • Biotechnology
  • Retail
  • Sportswear

The stock market in 2025 resembles a chessboard of extremes. While volatility is shaking up markets, extraordinary opportunities are emerging in unexpected corners. Established giants are stumbling, but it is precisely sharp price declines that harbor explosive comeback potential. At the same time, commodity newcomers are catching the attention of investors, driven by a sharp rise in the price of gold. And global consumer brands? Their fundamental strength may surprise despite short-term turbulence. Three very different players perfectly illustrate this momentum: Danish pharmaceutical giant Novo Nordisk, Canadian gold explorer Dryden Gold, and Puma, a German sportswear manufacturer. Their stories could transform your portfolio.

Read

Commented by Nico Popp on August 11th, 2025 | 07:15 CEST

Platform strategies are shaking up the biotech market: BioNxt, Thermo Fisher Scientific, Evotec

  • Biotechnology
  • Biotech
  • Pharma
  • AI

In biotech, the all-or-nothing principle no longer applies. Instead of offering just one product, the platform economy is becoming the norm in the development of tomorrow's active ingredients. What does this mean? Companies are working together, sharing their technology, and thereby reducing their dependence on individual projects. Since each player can focus on its core competencies, new active ingredients are brought to market faster, and even innovations in niche areas can gain significant traction thanks to strong partners. We explain what platform economics means in the biotech sector and how investors can benefit from it.

Read

Commented by Fabian Lorenz on August 7th, 2025 | 07:30 CEST

Bayer and its billion-dollar problem! Evotec fails to impress analysts! AI stock NetraMark makes a splash!

  • Biotechnology
  • AI
  • Biotech
  • Pharma

More positive news for AI insider tip NetraMark. The Company has secured a new customer for its AI platform designed to improve clinical trials. This could bring an end to the stock's sideways trend. Analysts continue to see significant upside. In contrast, analysts are cautious about Bayer's quarterly figures. The surprise stock of the year so far is facing a significant setback. The billion-dollar problems in the US are back on the table, weighing heavily on the stock. And what is Evotec doing? The sale of its site in France is intended to contribute to the Company's profitability. However, this only briefly boosted sentiment on the stock market. In the meantime, the stock has shifted into reverse. Rightly so?

Read

Commented by Armin Schulz on August 7th, 2025 | 07:15 CEST

New Tariff Drama – How Novo Nordisk, Vidac Pharma, and BioNTech are using AI and oncology to counter protectionism

  • Biotechnology
  • Pharma
  • AI
  • Oncology

The global pharmaceutical industry is experiencing a historic double revolution in 2025: Artificial Intelligence is accelerating research and personalized therapies, while disruptive US tariffs of up to 250% are reshaping supply chains. These forces are colliding as innovation meets protectionism. The winners are mastering both. They are leveraging digital breakthroughs and circumventing trade barriers through strategic production relocation. Those who invest now stand to benefit from the race to shape the future of global healthcare markets. The area with the most promising growth is oncology. We take a closer look at three exciting companies from the pharmaceutical and biotech industries: Novo Nordisk, Vidac Pharma, and BioNTech.

Read

Commented by Armin Schulz on August 5th, 2025 | 07:30 CEST

Bayer, PanGenomic Health, Novo Nordisk: 3 stocks that could benefit from the USD 330 billion tech tsunami!

  • Health
  • healthtech
  • Biotechnology
  • Pharma
  • AI

In 2025, the healthcare industry is being hit by a tech tsunami. Telemedicine and digital applications are revolutionizing diagnostics and treatment. Driven by AI, regulatory tailwinds, and rising patient demand, the market is exploding. Forecasts predict growth of up to USD 330 billion by 2029. Investors sense billion-dollar opportunities, especially where biotech meets big data and personalized solutions emerge. To benefit from these developments, key players like Bayer, PanGenomic Health, and Novo Nordisk are already positioning themselves today. We take a closer look at all three.

Read

Commented by Armin Schulz on August 5th, 2025 | 07:20 CEST

Evotec, NetraMark Holdings, and Pfizer: How to leverage the hidden biotech boom for returns!

  • Biotechnology
  • Biotech
  • AI
  • Pharma

Despite volatile markets, the healthcare sector is showing remarkable resilience. While the sector ETF is weakening, numerous companies are exceeding quarterly forecasts – especially in the biotech segment. Surprising earnings strength and innovative therapies are driving momentum, with even established pharmaceutical giants overcoming patent cliffs. This selectivity creates opportunities: those who identify the right players with disruptive technologies or strategic depth can benefit. Three names are particularly noteworthy here: Evotec, NetraMark Holdings, and Pfizer. We take a look at which companies have potential.

Read

Commented by Stefan Feulner on August 5th, 2025 | 07:00 CEST

Xiaomi, Almonty Industries, and BioNTech achieve strategic milestones

  • Mining
  • Tungsten
  • Biotechnology
  • consumergoods

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting the supply of important minerals to Western defense companies, which are needed for everything from ammunition to fighter jets. This development is prompting manufacturers to urgently seek alternative global sources for such critical raw materials to ensure continued production. One producer in particular has come to the forefront in recent weeks, as it can solve the shortage of the essential metal tungsten for the Western world.

Read

Commented by Armin Schulz on August 1st, 2025 | 07:10 CEST

Evotec's turnaround, Veganz Group's record year, Puma's relaunch: Your profit roadmap through the market shift!

  • Food
  • Vegan
  • Biotechnology
  • Retail

Germany's stock market is highly polarized in July 2025. While some heavyweights are struggling, others are shining with record results. This volatility is fueled by interest rate fears, disruptive changes, and the growing pressure of the sustainability transformation. In this complex environment, three stocks offer striking contrasts: A biotech pioneer is fighting its way back after painful setbacks through strategic realignments. A vegan food manufacturer is celebrating a record year with skyrocketing share prices and new profits. A sporting goods giant, on the other hand, is deep in a repositioning process after disappointing forecasts and management changes. Discover the opportunities and risks at Evotec, Veganz, and Puma.

Read